
X
AbbVie scores crucial phase 3 wins with Humira follow-up Skyrizi
https://pharmaphorum.com/news/abbvie-scores-crucial-phase-3-wins-with-humira-follow-up-skyrizi/
Swiss pharma hopes to bounce back from Q1 sales disappointment
Trials will cover psoriatic arthritis and ankylosing spondylitis
Xeljanz is first JAK inhibitor approved in psoriatic arthritis
Psoriasis drug surges in Q2.